Primer: BrainAurora Medical Technology (6681 HK) - Aug 2026
BrainAurora Medical Technology is a pioneer in China's nascent and rapidly growing digital therapeutics (DTx) market for cognitive impairment,...
93 Views
APAC Healthcare Weekly (August 23) – Henlius Bio, Wuxi XDC, Chugai Pharma, Daiichi Sankyo, Celltrion
Henlius strikes biosimilar commercialization deal with Sandoz. Chugai signs exclusive license deal with GSK for anti-dengue virus antibody....
100 Views
BrainAurora (6681 HK) Placement: A Good Entry Point Given the Growth Outlook, R&D Capabilities
​BrainAurora Medical (6681 HK) announced placement of 92M shares at HK$5.6/share for R&D, market development, and acquisition. The share placement...
293 Views
APAC Healthcare Weekly (April 5) – Henlius Biotech, InSilico, Shionogi, Samsung Bio, SK Biopharma
Henlius’ serplulimab is a step ahead for EU approval for two indications. InSilico inked $2.75B deal with Lilly. SK Biopharmaceuticals applied for...
335 Views
APAC Healthcare Weekly (March 29) – Hansoh, CSPC, Chugai, Takeda, Otsuka, Celltrion, Alteogen
Hansoh got trial approval, while CSPC obtained new drug approval. Chugai’s partner is discontinuing development of emugrobart. Otsuka is acquiring...
336 Views